Evidence map›Paper›PMID 25207097›Full record

ArticleBalkan medical journal2013

Clinical Features and Prognostic Factors of Hodgkin's Lymphoma: A Single Center Experience.

Saadettin Kılıçkap, Ibrahim Barışta, Sükran Ulger, Ismail Celik, Uğur Selek, Ferah Yıldız, Ayşe Kars, Yavuz Ozışık, Gülten Tekuzman

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Balkan medical journal, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 2 pooled it
0.4field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 2 syntheses or guidelines pooled it, 18 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. [Mechanism by which mycobacterial antigen 85B inhibits autophagy and promotes apoptosis in Hodgkin lymphoma cells].Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics · 2024
    Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Saadettin KılıçkapDepartment of Medical Oncology, Cumhuriyet University Faculty of Medicine, Sivas, Turkey.
Ibrahim BarıştaDepartment of Medical Oncology, Hacettepe University Institute of Oncology, Ankara, Turkey.
Sükran UlgerDepartment of Radiation Oncology, Hacettepe University Institute of Oncology, Ankara, Turkey.
Ismail CelikDepartment of Medical Oncology, Hacettepe University Institute of Oncology, Ankara, Turkey.
Uğur SelekDepartment of Radiation Oncology, Hacettepe University Institute of Oncology, Ankara, Turkey.
Ferah YıldızDepartment of Radiation Oncology, Hacettepe University Institute of Oncology, Ankara, Turkey.
Ayşe KarsDepartment of Medical Oncology, Hacettepe University Institute of Oncology, Ankara, Turkey.
Yavuz OzışıkDepartment of Medical Oncology, Hacettepe University Institute of Oncology, Ankara, Turkey.
Gülten TekuzmanDepartment of Medical Oncology, Hacettepe University Institute of Oncology, Ankara, Turkey.
Hacettepe University Hospital · TRSivas Cumhuriyet Üniversitesi · TR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundHodgkin's lymphoma (HL) is a B cell lymphoma characterized by the presence of Reed-Sternberg cells. HL comprises 1% of all cancer cases and 14% of all lymphoma cases.

aimsWe designed a retrospective study to investigate the clinical features and prognostic factors of HL patients diagnosed at an experienced oncology centre. STUDY

designRetrospective study.

methodsDemographic characteristics, histopathological and clinical features, treatment modalities and response to treatment were obtained from hospital records. Dates of initial diagnosis, remission and relapse, last visit and death were recorded for survival analyses.

resultsWe analysed data of 391 HL patients (61% male, 39% female; mean age 35.7±15.1 years). The most common classical HL histological subtype was nodular sclerosing HL (NSHL) (42.7%). The most common stage was II 50.4%. The most common chemotherapy regimen was doxorubicin, bleomycin, vinblastine and dacarbazine (ABVD) (70.6%). Five and 10-year survival rates were 90% and 84%, respectively. Early-stage patients with good prognostic factors had better overall and relapse-free survival rates. The presence of "B" symptoms, albumin level, Eastern Cooperative Oncology Group (ECOG) performance score, and LDH were prognostic factors that affect the survival in both univariate and multivariate analyses.

conclusionThis is the first study that demonstrates the demographic, clinical and prognostic features of HL patients in Turkey, and provides a general picture of the HL patients in our country.

Indexed as

diagnosisHodgkin’s lymphomaprognosistreatment

Identifiers

PMID25207097
PMCPMC4115978
OpenAlexW1977453103

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.